Richard S. Finn, MD

GI Oncology Now

<p>Richard Finn, MD, of the Geffen School of Medicine at UCLA, provides an update on recent developments in hepatocellular carcinoma treatment (HCC), highlighting key findings from studies involving immune checkpoint inhibitors targeting CTLA-4 and PD-1 pathways. Dr. Finn explains how the inclusion of patients with main portal vein invasion impacts outcomes in overall survival.</p>


Jessica Ganga

INTRIGUE: Final Overall Survival Analysis of Ripretinib Compared With Sunitinib in Patients With GIST

GIST

Benjamin Weinberg, MD, FACP

MATTERHORN, ATOMIC, CHALLENGE, and More: GI Oncology Updates from ASCO 2025

Colorectal Cancer

Nivolumab Plus Ipilimumab Shows Clinical Benefits for Patients With Advanced Colorectal Cancer

Latest News

ESMO 2024 Key Highlights in Liver Cancer: LEAP-012 and IMbrave050 Discussion

Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable